|
1）佐藤賢一，下瀬川徹．膵癌の病因と病態―膵癌発生から悪性化の分子機序―．日内会誌．2012; 101: 7-16
|
|
|
|
2）Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67: 1030-7
|
|
|
|
|
|
3）Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell stem cell. 2007; 1: 313-23
|
|
|
|
|
|
4）Li C, Wu JJ, Hynes M, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011; 141: 2218-27
|
|
|
|
|
|
5）Rasheed ZA, Yang J, Wang Q, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010; 102: 340-51
|
|
|
|
|
|
6）Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133: 704-15
|
|
|
|
|
|
7）Bao B, Wang Z, Ali S, et al. Notchi-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011; 307: 26-36
|
|
|
|
|
|
8）Bao B, Wang Z, Ali S, et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem. 2011; 112: 2296-306
|
|
|
|
|
|
9）Kabashima A, Higuchi H, Takaishi H, et al. Side population of pancreatic cancer cells predominates in TGF-b-mediated epithelial to mesenchymal transition and invasion. Int J Cancer. 2009; 124: 2771-9
|
|
|
|
|
|
10）Haque I, Mehta S, Majumder M, et al. Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer. 2011; 10: 8
|
|
|
|
|
|
11）Hamada S, Satoh K, Hirota M, et al. The homeobox gene MSX2 determines chemosensitivity of pancreatic cancer cells via the regulation of transporter gene ABCG2. J Cell Physiol. 2011; 227: 729-38
|
|
|
|
|
|
12）Nomura A, Banerjee S, Chugh R, et al. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Oncotarget. 2015; 6: 8313-22
|
|
|
|
|
|
13）Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012; 149: 656-70
|
|
|
|
|
|
14）Warburg O. On the origin of cancer cells. Science. 1956; 123: 309-14
|
|
|
|
|
|
15）Viale A, Pettazzoni P, Lyssiotis CA, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514: 628-32
|
|
|
|
|
|
16）Sainz B Jr, Alcala S, Garcia E, et al. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut. 2015. [Epub ahead of print]
|
|
|
|
|
|
17）Sainz B Jr, Martin B, Tatari M, et al. ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res. 2014; 74: 7309-20
|
|
|
|
|
|
18）Bailey JM, Alsina J, Rasheed ZA, et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in pre-invasive pancreatic cancer. Gastroenterology. 2014; 146: 245-56
|
|
|
|
|
|
19）Cioffi M, Trabulo SM, Sanchez-Ripoll Y, et al. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut. 2015. [Epub ahead of print]
|
|
|
|
|
|
20）Zhang Y, Liu L, Fan P, et al. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Oncotarget. 2015; 6: 9999-10015
|
|
|
|
|
|
21）Cioffi M, Trabulo S, Hidalgo M, et al. Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms. Clin Cancer Res. 2015; 21: 2325-97
|
|
|
|
|
|
22）Yen WC, Fischer MM, Axelrod F, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (Tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015; 21: 2084-95
|
|
|
|
|